Basking In Phase III Telaprevir Success, Vertex Maps Hepatitis C Market
After releasing glowing topline Phase III results for telaprevir, Vertex took pains to reassure investors that it is up to the commercial job of competing against Big Pharma and that it has done its homework on the developing hepatitis C market
You may also be interested in...
The first Phase III results for the hepatitis C direct-acting antiviral give the firm reason to be confident.
Following the acquisition of Schering-Plough, Merck has one of the most robust pipelines in the industry, but after an R&D day May 11, much of the most interesting data is still yet to be seen.
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011